TY - JOUR
AU - National COVID Testing Scientific Advisory Panel
AU - Crook, Derrick W.
AU - Screaton, Gavin R
AU - Adams, Emily R.
AU - Ainsworth, Mark
AU - Anand, Rekha
AU - Andersson, Monique
AU - Auckland, Kathryn
AU - Baillie, J. Kenneth
AU - Barnes, Eleanor
AU - Beer, Sally
AU - Bell, John I.
AU - Berry, Tasmin
AU - Bibi, Sagida
AU - Carroll, Miles W.
AU - Chinnakannan, Senthil
AU - Clutterbuck, Elizabeth A.
AU - Cornall, Richard
AU - de Silva, Thushan I.
AU - Dejnirattisai, Wanwisa
AU - Dingle, Kate
AU - Dold, Christina
AU - Espinosa, Alexis
AU - Eyre, David W.
AU - Farmer, Helen
AU - Mendoza, Maria
AU - Georgiou, Dominique
AU - Hoosdally, Sarah
AU - Hunter, Alastair
AU - Jeffery, Katie
AU - Kelly, Dominic F.
AU - Klenerman, Paul
AU - Knight, Julian C.
AU - Knowles, Clarice
AU - Kwok, Andrew J
AU - Leuschner, Ullrich
AU - Levin, Robert
AU - Liu, Chang
AU - López-Camacho, César
AU - Martinez, Jose
AU - Matthews, Philippa C.
AU - McGivern, Hannah
AU - Mentzer, Alexander J.
AU - Milton, Jonathan
AU - Mongkolsapaya, Juthathip
AU - Moore, Shona C.
AU - Oliveira, Marta S.
AU - Pereira, Fiona
AU - Perez, Elena
AU - Peto, Timothy E.A.
AU - Ploeg, Rutger J.
AU - Pollard, Andrew J.
AU - Prince, Tessa
AU - Roberts, David J.
AU - Rudkin, Justine
AU - Sanchez, Veronica
AU - Semple, Malcolm G.
AU - Slon-Campos, Jose
AU - Skelly, Donal
AU - Smith, Elliot Nathan
AU - Sobrinodiaz, Alberto
AU - Staves, Julie
AU - Stuart, David I.
AU - Supasa, Piyada
AU - Surik, Tomas
AU - Thraves, Hannah
AU - Tsang, Pat
AU - Turtle, Lance C.W.
AU - Walker, A. Sarah
AU - Wang, Beibei
AU - Washington, Charlotte
AU - Watkins, Nicholas
AU - Whitehouse, James
PY - 2020
DA - June
TI - Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
JO - Wellcome Open Research
VL - 5
DO - https://doi.org/10.12688/wellcomeopenres.15927.1
AB - Background: The COVID-19 pandemic caused &gt;1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices. Methods: We tested plasma for COVID (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142). Results: ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar. Conclusions: Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.
PB - Wellcome Open Research
UR - https://www.research.ed.ac.uk/portal/en/publications/antibody-testing-for-covid19(668dd302-21ab-4d32-9380-98766772c13c).html
KW - Coronavirus (COVID-19)
ER